Loading...

FITC anti-mouse CD206 (MMR) Antibody

Pricing & Availability
Clone
C068C2 (See other available formats)
Regulatory Status
RUO
Other Names
MMR (macrophage mannose receptor), MR (mannose receptor), MRC1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
C068C2_FITC_1_072111
Thioglycollate-elicited Balb/c macrophages were fixed/pemeabilized, and then stained with CD107b (Mac-3) APC and CD206 (clone C068C2) FITC (top) or rat IgG2a, κ FITC isotype control (bottom).
  • C068C2_FITC_1_072111
    Thioglycollate-elicited Balb/c macrophages were fixed/pemeabilized, and then stained with CD107b (Mac-3) APC and CD206 (clone C068C2) FITC (top) or rat IgG2a, κ FITC isotype control (bottom).
  • C068C2_FITC_2_072111
Compare all formats See FITC spectral data
Cat # Size Price Save
141703 50 µg ¥29,920
141704 200 µg ¥71,060
Description

CD206, also known as mannose receptor (MR), is a 175 kD type I membrane protein. It is a pattern recognition receptor (PRR) belonging to the C-type lectin superfamily. MR is expressed on macrophages, dendritic cells, Langerhans cells, and hepatic or lymphatic endothelial cells. MR recognizes a range of microbial carbohydrates bearing mannose, fucose, or N-acetyl glucosamine through its C-type lectin-like carbohydrate recognition domains, sulfated carbohydrate antigens through its cysteine-rich domain, and collagens through its fibronectin type II domain. MR mediates endocytosis and phagocytosis as well as activation of macrophages and antigen presentation. It plays an important role in host defense and provides a link between innate and adaptive immunity. Recently, MR on lymphatic endothelial cells was found to be involved in leukocyte trafficking and a contributor to the metastatic behavior of cancer cells. It suggests that MR may be a potential target in controlling inflammation and cancer metastasis by targeting the lymphatic vasculature.

Product Details
Technical data sheet

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Recombinant mouse CD206 (MMR)
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

ICFC - Quality tested
FC - Verified
Recommended Usage

Each lot of this antibody is quality control tested by intracellular immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.125 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Blue Laser (488 nm)
Application Notes

Clone C068C2 recognizes a region similar to clone MR5D3, based on the ability of the clones to block each other. Additional reported applications (for the relevant formats) include: spatial biology (IBEX)4,5.

Application References

(PubMed link indicates BioLegend citation)
  1. Keller J, et al. 2012. Biochem Biophys Res Commun. 417:217. PubMed
  2. Ito H, et al. 2012. J Am Soc Nephrol. 23:1797. PubMed
  3. Yang X, et al. 2015. PNAS. 112:2900. PubMed
  4. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  5. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Oliver AJ, et al. 2020. Oncoimmunology. 9:1802979. PubMed
  2. Yang Q, et al. 2022. Br J Pharmacol. 179:1661. PubMed
  3. Liang X, et al. 2022. Cancer Commun (Lond). 42:205. PubMed
  4. Luo XB, et al. 2022. Ann N Y Acad Sci. 1514:116. PubMed
  5. Pannunzio B, et al. 2022. Cells. 11: . PubMed
  6. Ding L, et al. 2023. Immunology. 168:49. PubMed
  7. Napier TS, et al. 2023. Biomedicines. 11: . PubMed
  8. Han J, et al. 2023. Front Microbiol. 13:1067725. PubMed
  9. Zhu X, et al. 2023. Front Immunol. 14:1114802. PubMed
  10. Kraynak CA, et al. 2022. Int J Pharm. 618:121634. PubMed
  11. Sun L, et al. 2021. Cancer Cell. 39:1361. PubMed
  12. Liang S, et al. 2019. Mol Med Rep. 19:3707. PubMed
  13. Valanparambil RM, et al. 2017. PLoS Pathog. 13:e1006647. PubMed
  14. Bajaj R, et al. 2022. Cell Rep. 40:111429. PubMed
  15. An S, et al. 2022. Int J Mol Sci. 23:. PubMed
  16. Chen H, et al. 2023. Nat Commun. 14:941. PubMed
  17. Roussel-Queval A, et al. 2023. STAR Protoc. 4:102119. PubMed
  18. Do-Thi VA, et al. 2023. Cancer Res Commun. 3:80. PubMed
  19. Ishida K, et al. 2023. Front Immunol. 14:1111729. PubMed
  20. Wang C, et al. 2023. Int J Oral Sci. 15:19. PubMed
  21. Yang Y, et al. 2023. Diagnostics (Basel). 13:. PubMed
  22. Yashchenko A, et al. 2023. Front Immunol. 14:1082078. PubMed
  23. Meng W, et al. 2021. JCI Insight. 6:. PubMed
  24. Keane T, et al. 2012. Biomaterials. 33:1771. PubMed
  25. Miao L, et al. 2020. Theranostics. 0.7625. PubMed
  26. Kesavan R, et al. 2021. Int J Mol Sci. 22:. PubMed
  27. Zakeri A, et al. 2021. J Extracell Vesicles. 10:e12131. PubMed
  28. Choi B, et al. 2017. Eur J Pharmacol. 10.1016/j.ejphar.2017.07.022. PubMed
  29. Song C, et al. 2019. Nat Commun. 10:3745. PubMed
  30. Li C, et al. 2022. Theranostics. 12:4581. PubMed
  31. Ma C, et al. 2022. Proc Natl Acad Sci U S A. 119:. PubMed
  32. Zhang W, et al. 2021. Front Immunol. 12:688294. PubMed
  33. Wada I, et al. 2021. Invest Ophthalmol Vis Sci. 62:17. PubMed
  34. Eastman A, et al. 2016. J Immunol . 194: 5999-6010. PubMed
  35. Lee S, et al. 2015. PLoS One. 10: 0132329. PubMed
  36. Hindi S, et al. 2012. Mol Cell Biol. 32:4833. PubMed
  37. Wu R, et al. 2019. J Cell Mol Med. 24:1684. PubMed
  38. Song M, et al. 2021. J Immunol Res. 6696606:2021. PubMed
  39. Uroda T, et al. 2020. Nat Protoc. 15:2107. PubMed
  40. Li H, et al. 2019. J Immunol Res. 2018:4807145. PubMed
  41. Li K, et al. 2022. J Immunother Cancer. 10:. PubMed
  42. Yang Y, et al. 2022. Regen Biomater. 9:rbac023. PubMed
  43. Forni MF, et al. 2021. Front Oncol. 11:667715. PubMed
  44. Ma J, et al. 2021. Curr Protoc. 1:e144. PubMed
  45. Shin JE, et al. 2021. Heliyon. 7:e08433. PubMed
  46. Amo-Aparicio J, et al. 2021. Theranostics. 11:9805. PubMed
  47. Li Z, et al. 2022. J Exp Clin Cancer Res. 41:74. PubMed
  48. Guo L, et al. 2021. Front Immunol. 12:785457. PubMed
  49. Nguyen TKT, et al. 2020. Am J Pathol. 286:190. PubMed
  50. Yin S, et al. 2016. Nat Commun. 7: 11311. PubMed
  51. Yin T, et al. 2016. Sci Rep. 18:19534. PubMed
  52. Linde N, et al. 2018. Nat Commun. 9:21. PubMed
  53. Shi R, et al. 2022. Theranostics. 12:875. PubMed
  54. Lee SS, et al. 2022. Commun Biol. 5:654. PubMed
  55. Vigeland C, et al. 2016. PLoS One. 11: 0163288. PubMed
  56. Lu CS, et al. 2020. J Hematol Oncol. 0.584722222. PubMed
  57. Li N, et al. 2021. eLife. 10:00. PubMed
  58. Neupane AS, et al. 2020. Cell. 183(1):110-125.e11. PubMed
  59. Zhang F, et al. 2017. Mol Immunol. 10.1016/j.molimm.2017.06.019. PubMed
  60. Lin S, et al. 2022. Nat Commun. 13:3301. PubMed
  61. Sun L, et al. 2015. J Immunol. 194:4891. PubMed
  62. Kida Y, et al. 2013. J Am Soc Nephrol. 24:559. PubMed
  63. Wang W, et al. 2018. Oncogenesis. 7:97. PubMed
  64. Xie Z, et al. 2018. J Am Heart Assoc. 7:e007442. PubMed
  65. Ishii H, et al. 2012. Cell Death Dis. 9;3:e363. PubMed
  66. Wang T, et al. 2018. Front Physiol. 9:209. PubMed
  67. Lu J, et al. 2021. Cell Death Discov. 7:165. PubMed
  68. Tomay F, et al. 2019. J Transl Med. 17:237. PubMed
  69. Zhou T, et al. 2022. Sci Adv. 8:eabj9617. PubMed
  70. Guan X, et al. 2022. Nat Commun. 13:2834. PubMed
  71. Yang Y, et al. 2020. Cancer Biol Ther. 522:21. PubMed
  72. Galle-Treger L, et al. 2019. Nat Commun. 10:713. PubMed
  73. Genoula M, et al. 2018. Front Immunol. 9:459. PubMed
  74. Zimmerman KA, et al. 2019. J Am Soc Nephrol. 30:1841. PubMed
  75. Miki Y, et al. 2022. JCI Insight. 7:. PubMed
  76. Zhang S, et al. 2022. Nat Commun. 13:4744. PubMed
  77. Shibata T, et al. 2020. J Clin Invest. 130:3021. PubMed
  78. Li Y, et al. 2015. Sci Rep. 5: 18648. PubMed
  79. Ano Y, et al. 2019. Nutrients. 1.959027778. PubMed
  80. Makino A, et al. 2021. iScience. 24:103201. PubMed
  81. Wang S, et al. 2022. J Inflamm Res. 14:7107. PubMed
  82. Liu Y, et al. 2015. BioMed Res Int. 2015 563425. PubMed
  83. Shen L, et al. 2016. Sci Rep. 6:30347. PubMed
  84. Cuccarese M, et al. 2017. Nat Commun. 8:14293. PubMed
  85. Yuan Y, et al. 2020. Front Physiol. 0.967361111. PubMed
  86. Laban H, et al. 2018. J Cell Biol. 217:1503. PubMed
  87. Wang X, et al. 2021. Cell. 184:5357. PubMed
  88. de Assis LVM, et al. 2022. Commun Biol. 5:461. PubMed
  89. Kaji T, et al. 2012. J Exp Med. 80:3642. PubMed
  90. Grayczyk JP et al. 2017. Cell host & microbe. 22(5):678-687 . PubMed
  91. Wang D, et al. 2021. Nan Fang Yi Ke Da Xue Xue Bao. 41:775. PubMed
  92. Zhang A, et al. 2021. Theranostics. 11:3839. PubMed
  93. Madsen CS, et al. 2022. Commun Biol. 5:888. PubMed
  94. Wang S, et al. 2020. J Cell Mol Med. 24:722. PubMed
  95. Yoshida H, et al. 2019. Cell. 176:897. PubMed
  96. McAusland TM, et al. 2021. Mol Ther Oncolytics. 20:306. PubMed
  97. Medina-Buelvas DM, et al. 2021. Pathogens. 10:. PubMed
  98. Gao R, et al. 2021. J Clin Invest. 131:. PubMed
  99. Chen Y, et al. 2021. Cancer Cell. 39(4):548-565.e6. PubMed
  100. Xue YL, et al. 2020. J Cell Mol Med. 24:12341. PubMed
  101. Zhang J, et al. 2014. J Immunol. 193:5149. PubMed
  102. Fransén Pettersson N, et al. 2018. PLoS One. 13:e0203228. PubMed
  103. Hartwig T et al. 2017. Molecular cell. 65(4):730-742 . PubMed
  104. Gu L, et al. 2017. FASEB J. 31:3072. PubMed
  105. Perrotta C, et al. 2018. Front Immunol. 9:1186. PubMed
  106. Chen Z, et al. 2016. Innate Immunity. 22: 419 - 432. PubMed
  107. Hall JA, et al. 2020. Cell Metabolism. 32(4):665-675.e6. PubMed
  108. Wu L, et al. 2020. Cancer Immunol Res. 710:8. PubMed
  109. Kim YD, et al. 2020. J Cancer. 11:4059. PubMed
  110. Scheyltjens I, et al. 2022. Nat Protoc. 17:2354. PubMed
  111. Xue Y, et al. 2020. Sci Rep. 10:22265. PubMed
  112. Kapralov AA, et al. 2020. Nat Chem Biol. 278:16. PubMed
  113. Li J, et al. 2021. eLife. 10:00. PubMed
  114. Xiang W, et al. 2020. Signal Transduct Target Ther. 0.374305556. PubMed
  115. Yao Y, et al. 2016. Mol Ther. 10.1038/mt.2016.36. PubMed
  116. Kim SH, et al. 2020. Neoplasia. 1.3375. PubMed
  117. Yuan C, et al. 2020. Braz J Med Biol Res. 53:e9488. PubMed
RRID
AB_10901166 (BioLegend Cat. No. 141703)
AB_10901166 (BioLegend Cat. No. 141704)

Antigen Details

Structure
Type I transmembrane protein, 175 kD, C-type lectin superfamily
Distribution

Macrophages, dendritic cells, Langerhans cells, liver endothelial cells

Function
Pathogen recognition, endocytosis and phagocytosis, antigen presentation
Ligand/Receptor
Antigen containing mannose, fucose, or an N-acetyl glucosamine
Cell Type
Dendritic cells, Endothelial cells, Langerhans cells, Macrophages
Biology Area
Cell Biology, Immunology, Innate Immunity, Signal Transduction
Molecular Family
CD Molecules
Antigen References

1. Wileman TE, et al. 1986. P. Natl. Acad. Sci. USA 83:2501.
2. Apostolopoulos V, et al. 2001. Curr. Mol. Med. 1:469.
3. Burgdorf S, et al. 2006. J. Immunol. 176:6770.
4. McKenzie EJ, et al. 2007. J. Immunol. 178:4975.

Gene ID
17533 View all products for this Gene ID
UniProt
View information about CD206 on UniProt.org

Related FAQs

Why is mouse CD206 stained intracellularly and not via surface staining?

Typically, mouse CD206 surface level is relatively low under normal conditions and so intracellular staining protocol is required to get better signal.

Go To Top Version: 4    Revision Date: 04/04/2016

For Research Use Only. Not for diagnostic or therapeutic use.

 

This product is supplied subject to the terms and conditions, including the limited license, located at www.biolegend.com/terms) ("Terms") and may be used only as provided in the Terms. Without limiting the foregoing, BioLegend products may not be used for any Commercial Purpose as defined in the Terms, resold in any form, used in manufacturing, or reverse engineered, sequenced, or otherwise studied or used to learn its design or composition without express written approval of BioLegend. Regardless of the information given in this document, user is solely responsible for determining any license requirements necessary for user’s intended use and assumes all risk and liability arising from use of the product. BioLegend is not responsible for patent infringement or any other risks or liabilities whatsoever resulting from the use of its products.

 

BioLegend, the BioLegend logo, and all other trademarks are property of BioLegend, Inc. or their respective owners, and all rights are reserved.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account